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osting by EAbstract Background: EGFR is involved in the epidermal growth factors pathway that regulates
cellular processes and is associated with the development of many types of cancer including colo-
rectal cancer. Molecular methods with high sensitivity such as nested polymerase chain reaction
(PCR) based assays have been used to search for tumor cell speciﬁc markers. This study aimed
to detect the circulating EGFRmRNA expressing tumor cells and its diagnostic value in colorectal
cancer compared with that of known markers of circulating cancer cells CEA and CK20.
Subjects and methods: This study included 36 patients diagnosed as having colon cancer of different
stages and 18 matched healthy controls. The staging was carried out according to the TNM classi-
ﬁcation. We used nested RT-PCR-based reverse transcription PCR assay for the detection of circu-
lating cancer cells in the peripheral blood.
Results: The blood samples from the colon cancer patients showed detection of EGFR in 15/36
patients (41.7%); CEAmRNA in 22/36 patients (61.1%) and CK20mRNA in 24/36 patients
(66.7%). No evidence of EGFR mRNA expression in any of the samples used as controls. 3/18
(16.7%) and 4/18 (22.2%) of healthy controls gave a positive result of CEA/CK20mRNAs. There
was a statistically signiﬁcant difference in the prevalence of EGFR/CEA and CK20mRNAs expres-
sion between the early disease group (stage I and II) and the advanced disease group (stage III
and IV) (P< 0.01). Colon cancer patients with a high level of serum CEA exhibited detectableo.com (S.H. Teama).
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174 S.H. Teama, S.H.A. Agwaconcentrations of EGFR and CEA and CK20mRNAs more often than those with a low serum
CEA level, there is signiﬁcant difference (P< 0.01).
Conclusion: EGFR assay might represent a suitable marker for detection of circulating tumor cells
in colon cancer patients. CEA and CK20mRNAs are signiﬁcantly more frequently detected in colon
cancer patients than in healthy controls supports the hypothesis that they are promising comple-
mentary markers for CRC diagnosis. The assessment of multiple molecular tumor markers
improved the sensitivity in detecting circulating tumor cells but due to limited speciﬁcity; identiﬁca-
tion and validation of genes and proteins implicated in metastatic processes need to be further
investigated.
 2010 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer is currently the third most common type
of cancer in both men and women and the third leading
cause of cancer death. The incidence of colorectal cancer
begins to rise at age 40 and peaks between ages 60 and
75 [1]. A recent report published by Egypt’s National Can-
cer Institute revealed that colon cancer is the third most
dangerous type of cancer that causes death in the country.
The report said that it found that infection rates range from
10 to 12 percent of the total cancer cases annually reported
in Egypt.
Metastatic spreading through blood vessels is the most
important factor affecting the prognosis of patients with pri-
mary carcinomas [2]. The detection of circulating tumor cells
has crucial prognostic and therapeutic implications in all can-
cer patients [3]. The question is whether circulating tumor cells
represent metastatic dissemination or are merely cancer cells
without metastatic potential that have detached from the pri-
mary tumor.
The most widely used screening technique for colorectal
cancer is the fecal occult blood test. However, this simple, inex-
pensive, and noninvasive test is heavily prone to produce not
only false positive results but also false negative results because
colorectal tumors bleed intermittently. On the other hand,
colonoscopy, which has very high diagnostic accuracy in terms
of both sensitivity and speciﬁcity, is characterized by a moder-
ate compliance because it is invasive and not without poten-
tially adverse events. Its use is limited to second-level
diagnostic tests within screening programs [4]. Numerous ser-
um markers, such as carcinoembryonic antigen (CEA), carbo-
hydrate antigen 19–9, and lipid-associated sialic acid, have
been investigated in colorectal cancer, but their low sensitivity
has induced the American Society of Clinical Oncology to state
that none can be recommended for screening and diagnosis
and that their use should be limited to postsurgery surveillance
[5,6]. Cytokeratines (CKs); CK18, CK19, and CK20 are gener-
ally used for the detection of most epithelial cell type tumors.
Recently; the epidermal growth factor receptor (EGFR) is
widely used.
Epidermal growth factor receptor (EGFR) is over
expressed in 50–70% of human primary breast, lung and
colon carcinoma, whereas it is not usually expressed in
hematopoietic cells. It is a 170-kDa transmembrane glyco-
protein/cell surface receptor composed of an extracellular li-
gand binding domain, a transmembrane lipophilic segment
and an intracellular tyrosine kinase [7,8]. Epidermal growthfactor receptor belongs to the ErbB tyrosine kinase recep-
tor family which includes four proteins encoded by the c-
erb B proto-oncogene, namely ErbB1 (EGFR), ErbB2
(HER2/neu), ErbB3 (HER3) and ErbB4 (HER4). Ligand
binding produces dimerization of the receptor and activa-
tion of intrinsic protein tyrosine kinase activity leading to
the transduction of signaling pathways involved in prolifer-
ation, cell division and differentiation. The MAP kinase
and AKT signaling pathways have been found to mediate
intracellular EGFR signaling. The biologic responses to
MAP kinase induction result in increased expression of
proteins governing cell-cycle regulation. AKT, an anti-
apoptotic kinase, is implicated in cell survival and promo-
tion of angiogenesis and has also been linked to activation
of matrix metalloproteinase protein facilitating tumor
growth and promotion [9].
Carcinoembryonic antigen (CEA), the gene forCEA is oneof
the most widely expressed genes in cancer cells. It is a glycopro-
tein involved in cell adhesion. It is normally produced during fe-
tal development, but the production of CEA stops before birth.
Therefore, it is not usually present in the blood of healthy adults.
The gene for CEA is one of the most widely expressed genes in
cancer cells. It is expressed in 95% of colorectal, gastric, and
pancreatic cancers; in themajority of non-small cell lung cancers
and other carcinoma types, such as squamous cell cancer of the
head and neck; and in 50% of breast cancers [10].
Cytokeratines (CKs) belong to the intermediate ﬁlament sys-
tem and can be divided into ﬁve classes according to their bio-
chemically distinct subunits. Cytokeratins are almost
exclusively expressed in epithelial tissues and have therefore
been used to detect disseminated tumor cells of epithelial origin
[11–13].
Cytokeratin 20 (CK20), tumor marker is expressed in pan-
creatic, gastric and colorectal cancers. Further, CK20 expres-
sion has been shown in normal colonic epithelial cells as well
as in cells of patients with colorectal and stomach cancers. Re-
cently, a CK20 expression pattern characterized 100% of pri-
mary and 88% of metastatic colorectal adenocarcinoma
[14–16]. In other reports, the expression of CK20 has been
shown to be almost entirely restricted to gastric and intestinal
epithelium, urothelium and Merkel cells [17,18].
The current study aimed both to evaluate the feasibility of
detection of cancerous cells in the peripheral blood of colon
cancer patients based on the nested RT-PCR ampliﬁcation
of EGFR mRNA with the simultaneous identiﬁcation of
CEA/CK20mRNAs and to examine the clinical signiﬁcance
of our ﬁndings.
Table 1 Sequences of oligonucleotide primers used for PCR
reaction.
Primers Sequence of primers (50–30) (bp)
EGFR primer 2
Outer-sense TCTCAGCAACATGTCGATGG
Outer-antisense TCGCACTTCTTACACTTGCG 473
Inner-sense TCTCAGCAACATGTCGATGG
Inner-antisense TCACATCCATCTGGTACGTG 322
CEA primer 1
Outer-sense CCATGGAGTCTCCCTCG
Outer-antisense GTAGCTTGCTGTGTCATTTC 641
Inner-sense AGGTGCTTCTACTTGTCCACAA
Inner-antisense GCCAGTTGCTTCTTCATTCA 260
CK20 primer 1
Outer-sense CAGACACACGGTGAACTATGG
Outer-antisense GATCAGCTTCCACTGTTAGAGACG 371
Inner-sense GTTGGCAATGAGAAAATGGC
Inner-antisense GCATCCTTAATCTGACTTCGCA 203
GAPDH primer
Sense CTACTGGCG CTG CCA AGG CTG T
Anti sense GCCATG AGG TCC ACC ACCCTG T 390
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2.1. Subjects
This study included 54 subjects classiﬁed into two main
groups:
I. Patients group: Included 36 patients diagnosed as having
colon cancer and conﬁrmed by pathological examination of
the biopsies. Clinical and histological staging was as follows:
stage I, 6 (16.7); stage II, 9 (25%); stage III, 10 (27.8%); stage
IV, 11 (30.5%).
II. Control group: Included 18 apparently healthy people of
matched age and sex as the malignant group.
All the patients involved in the study were chosen
from Internal Medicine Department; Ain Shams Hospital
from December 2009 to May 2010. All subjects provided
their informed consent to participate in the study. Each
patient was subjected to full history taking, complete gen-
eral and abdominal examination; laboratory evaluation;
imaging investigation (abdominal ultrasonography and
C.T).
2.2. Methods
2.2.1. Blood samples
Blood samples from the peripheral veins from each patient and
controls were collected into two tubes; EDTA tube blood for
RNA preparation and another plain tube blood for separation
of serum to detect CEA. To reduce the false positive risk from
needle cored epithelial cell entering the venesection needle lu-
men, an intravenous canula was inserted and 5 ml was aspi-
rated before sample collection.
For all the specimens collected of all groups, the following
procedures were carried out:
2.2.1.1. RNA preparation. Aliquots of peripheral blood were
processed within 1-h of being obtained from the patients.
The blood samples were mixed with 1 ml of 5%dextran-saline
solution and left to set for 30 min. at room temperature to
yield erythrocyte sediment. Supernatant was collected and cen-
trifuged at 500g for 10 min. at 4 C. The cells were then sus-
pended in 1 ml of nucleic acid extraction buffer and frozen
at 70 C until RNA extraction was performed.
2.2.1.2. Extraction of total RNA. Total RNA of nuclear cells
was extracted using RNA extraction kit (Qiagen) according
to the manufacturer’s instruction. All RNA preparation and
handling steps took place in a laminar ﬂow hood, under
RNAse-free conditions. The isolated RNA was resuspended
in RNAse-free water and stored at 80 C until assay. The
RNA concentration was assessed by absorbance reading at
260 nm with UV spectrophotometry (Beckman; Du series
650, INC, USA).
2.2.1.3. Ampliﬁcation by nested reverse transcriptase polymerase
chain reaction (RT-PCR). Three different PCR reactions were
performed with each sample in order to amplify fragments of
EGFR/CEA and CK20mRNAs.Reverse Transcription (Complementary cDNA synthesis):
Reverse transcription reaction was carried out in 20 lL reac-
tion mixture using 2 lg of RNA by using ﬁrst strand cDNA
synthesis kit (Promega; USA) according to manufacturer’s
instruction.
Nested PCR for EGFR/CEA/CK20mRNAs: A total amount
of 50 lL reaction solution contained 5 lL 10· PCR buffer,
0.2 mmol/L of each dNTP, 30 pmol of each primer, 2.5U
Taq DNA polymerase (Promega; USA) and cDNA. Thermo-
cycling in either an MJ Research PTC 200 (MJ Research, Inc.,
Boston, Mass.) or Perkin–Elmer 9600 (Perkin–Elmer, Cam-
bridge, United Kingdom) was done according to the following
cycle proﬁle. For sequences of oligonucleotide primers used for
PCR reaction see (Table 1).
Nested PCR for EGFR mRNA: Thirty cycles consisting of 5
cycles of 30 s at 94 C, 45 s at 60 C, and 45 s at 72 C and 25
cycles of 30 s at 94 C, 45 s at 55 C, and 45 s at 72 C; the sam-
ples were heated for 10 min. at 94 C before the ﬁrst cycle, and
the extension was lengthened to 10 min. during the last cycle.
After completion of the ﬁrst PCR reaction, 1 ll of the ﬁrst
PCR ampliﬁcation product was added to the second PCR
solution. The PCR conditions for the nested PCR reaction
were similar to those for the ﬁrst round PCR with the follow-
ing exception that the PCR number of cycles was 35 [2].
Nested PCR for CEA and CK20mRNAs were performed
as described by Lagoudianakis et al. 2009 [1].
To verify the successful preparation of mRNA, samples
were detected for the presence of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA. Analysis of each sample
was repeated at least two times.
2.2.1.4. Gel electrophoresis. The ﬁnal ampliﬁcation product
was electrophoresed on 2% agrose gel and stained with ethi-
dium bromide for the speciﬁc band of bp.
2.2.1.5. Assay for CEA. For the analysis of CEA; we used
commercially available kit (Roche, Mannheim, Germany).
     1       2       3       4       5       6       7      8 
322bp 
Lane 1: DNA molecular size marker
Lane 2: Positive control  
Lane 3: Negative control 
Lane 4,5: Positive cases of EGFR gene transcript 
Lane 6, 7: Negative cases
Figure 1 Shows the result of PCR product. Electrophoretic
separation of PCR ampliﬁed product; Detection of gene tran-
scripts in blood specimens from Colon cancer patients.
      1      2       3      4       5      6      7      8 
203bp 
Lane 1: DNA molecular size marker
Lane 2: Positive control
Lane 3: Negative control 
Lane 4,6,7: Positive cases of 
CK20 positive gene
Lane 5,8: Negative cases
Figure 3 Shows the result of PCR product. Electrophoretic
separation of PCR ampliﬁed product; Detection of gene tran-
scripts in blood specimens from Colon cancer patients.
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2.3. Statistical analysis
The results were analyzed using the Statistical Package of
Social Sciences (SPSS) computer software program, version
16.0 (Chicago, IL, USA). Data are presented as numbers
and percentages. Association between categorical groups was
evaluated using Chi-square or Fisher’s exact test when appro-
priate. A P value less than 0.05 was considered statistically
signiﬁcant.
3. Result
3.1. Interpretation of result
According to the design of primer pairs, the PCR products of
(322); (260) (203) base pairs were ampliﬁed from EGFR/CEA
and CK20 cDNA respectively; while GAPDH band ampliﬁca-
tion was visualized corresponding to 390 bp. The sizes of PCR260bp 
Lane 1: DNA molecular size marker
Lane 2,4,5,7: Negative Case
Lane 3,6,8: Cases showing CEA positive gene transcript
Figure 2 Shows the result of PCR product. Electrophoretic
separation of PCR ampliﬁed product; Detection of gene tran-
scripts in blood specimens from Colon cancer patients.products were estimated by comparison with DNA molecular
mass markers (Bio-Rad; EZ Load) (Figs. 1–3).
3.2. Patient characteristics
A total of 36 patients were enrolled in the study (20 male; 16
female). Demographic data are represented in (Table 2). Nei-
ther age nor sex was correlated with the presence of EGFR/
CEA and CK20mRNAs expression (P> 0.05).
3.2.1. Expression of EGFR/CEA/CK20mRNAs in peripheral
blood from healthy volunteers
A total of 18 RNA samples extracted from healthy volunteers
were subjected to RT-PCR. EGFR was not detected in any
sample. However, CEA and CK20mRNAs were detected in
3/18 (16.7%) and 4/18 (22.2%).
3.2.2. Expression of EGFR/CEA/CK20mRNAs in peripheral
blood from colon cancer patients
The blood samples from the 36 colon cancer patients showed
detection of EGFR in 15 patients (41.7%); CEAmRNA in
22 patients (61.1%) and CK20mRNA in 24 patients (66.7%)
and analysis of these results showed that EGFR/CEA/
CK20mRNAs expression showed a statistically signiﬁcant dif-
ference between healthy controls and cancer patients (Table 3,
Fig. 4).
The frequency of positive cases in TNM stage III and IV
was signiﬁcantly higher than that in stage I and II
(P< 0.05). Colon cancer patients with a high level of serum
CEA exhibited detectable concentrations of EGFR and CEA
and CK20mRNAs more often than those with a low serum
CEA level, thus there is signiﬁcant difference. These results
indicate that the incidence of the expression of cancer speciﬁc
molecular markers EGFR/CEA and CK20mRNAs increased
in advanced stage of disease and correlated with clinical sever-
ity (Table 4).
Table 2 Patients characteristics.
Normal Colon cancer patients P-value
No. of patients 18 36
Age 52.8 ± 10.1 55.8 ± 9.9 >0.05
Sex
Male 11 (61.1%) 20 (55.6%)
Female 7 (38.9%) 16 (44.4%)
Stage of disease
Stage I (Duke A) 6 (16.7%)
Stage II (Duke B) 9 (25%)
Stage III (Duke C) 10 (27.8%)
Stage IV (Duke D) 11 (30.5%)
Detection of circulating tumor cells by nested RT-PCR targeting EGFR/CEA/CK20mRNAs 177The detection of EGFRmRNA in peripheral blood is corre-
lated with that of CK20mRNA and no correlation was found
between EGFRmRNA and CEAmRNA (Table 5). The result
indicates that 25/36 (69.4%) were positive for at least one mar-
ker and 13/36 (36.1%) positive for the three molecular markers
which strongly indicate hematogenous spread.Table 3 Expression of EGFR/CEA and CK20mRNAs in peripher
mRNA expression Colon cancer patients (n= 36)
EGFR 15 (41.7%)
CEA 22 (61.1%)
CK20 24 (66.7%)
* Signiﬁcant difference between cancer patients and the healthy controls.
Table 4 Expression of EGFR/CEA and CK20mRNAs in relation
n EGFR P*
Gender
Male 20 8 (40%) 0.05
Female 16 7 (43.8%) 0.82
Stage of disease
Stage I 6 0 (0%)
Stage II 9 1 (11.1%) 12.32
Stage III 10 5 (50%) 0.001**
Stage IV 11 9 (81.8%)
Serum CEA
<5 14 1 (7.1%) 11.23
>5 22 14 (63.6%) 0.003
* Chi square test or Fisher’s exact test for small sample size.
** Signiﬁcant difference between stage (I and II) and (III and IV).
Table 5 Comparison of expression of marker genes in blood samp
n CK20
Negative Positive
EGFR
Negative 21 12 9
Positive 15 0 15
Total 36 12 244. Discussion
Colon cancer is one of the most common malignancies in the
world. With progress in diagnostic and therapeutic techniques,
its prognosis has been improving.
The spread or dissemination of cancer cells from the pri-
mary tumor is the most important factor affecting prognosis
in carcinoma patients. Once distant metastasis has been
formed, cancer disease is generally no longer curable and med-
ical intervention is restricted to palliative treatment. Hematog-
enous spread of solid cancers represents a major clinical
challenge in oncology and has a fundamental inﬂuence on
the outcome of the disease. Metastasis of solid malignancies
like breast and colorectal cancers has been referred to as a cas-
cade; in the beginning, cancer cells carrying multiple genetic
abnormalities grow unregulated and lose their ability to adhere
to each other. This, together with their ability to stimulate
angiogenesis, provides a means for entry to the blood and lym-
phatic circulation. In the case of the blood circulation, these
cells can circulate in the body until adhering to the vascular
endothelium when they can leave the circulation (extravasa-
tion) [19].al blood of colon cancer patients and healthy controls.
Healthy controls (n= 18) P-value
0 (0%) <0.05*
3 (16.7%)
4 (22.2%)
to gender, stage and serum CEA.
CEA P* CK20 P*
12 (60%) 2.33 12 (60%) 0.91
10 (62.5%) 0.17 12 (75%) 0.27
1 (16.7%) 0 (0%)
5 (55.6) 9.21 4 (44.4) 14.95
6 (60%) 0.01** 9 (90%) 0.001**
10 (90.9) 11 (100)
5 (35.7%) 6.21 4 (28.6%) 14.96
17 (77.2%) 0.01 20 (90.9%) 0.001
les of colon cancer patients.
P* CEA P*
Negative Positive
12.9 10 11 1.61
0.001 4 11 0.17
14 22
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Expression of EGFR/CEA/CK20mRNA in periphral blood
Healthy
Colon cancer
Healthy 22.20%16.70%0%
Colon cancer 66.70%61.10%41.70%
CK20CEAEGFR
Figure 4 Expression of EGFR/CEA/CK20mRNAs in peripheral blood.
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detection of cancer cells in the peripheral blood, bone marrow,
and lymph nodes of patients with several cancer types such as
breast, colon cancer, melanoma, neuroblastoma, prostate can-
cer, and lymphoma.
Data from the current study are as follows: The blood sam-
ples from the 36 colon cancer patients showed detection of
EGFR mRNA in 15 patients (41.7%); CEAmRNA in 22 pa-
tients (61.1%); CK20mRNA in 24 patients (66.7%) and our
data result is in agreement with many previous results [1,2].
All blood samples were scored positive for mRNA expression
only after performing an internal PCR.
4.1. EGFR
In our result, EGFR mRNA showed signiﬁcantly strong sta-
tistical difference between healthy controls and cancer pa-
tients. EGFR was not detected in any sample of healthy
volunteer. It can be concluded that in the majority of the pa-
pers reviewed, EGFR expression had been reported in 25–
82% of CRCs [20–23]. RT-PCR for EGFR can detect circu-
lating micrometastasis in a proportion of patients with ad-
vanced-stage cancers of epithelial origin, including lung,
colon, and pancreas.
It is well documented that EGFR expression may be asso-
ciated with an advanced disease stage [24–26]. Furthermore,
our data showed EGFR correlated to TNM stage. However,
these results remain controversial because an association be-
tween EGFR expression and Dukes stage or length of survival
in CRC has not been detected in other studies [27].
Finally, novel therapeutic approaches based on EGFR
blocking antibodies, EGFR tyrosine kinase inhibitors, or anti-
sense oligonucleotides directed against either EGFR or its li-
gands have been developed. EGFR assay could be used to
monitor the response of the tumor to these novel agents by
monitoring the level of EGFR positive cells shed by the carci-
noma during therapy.
4.2. CEA
We found that; there was a signiﬁcant high positive ratio of
CEA in the peripheral blood of CRC patients compared with
normal. CEA is in fact widely accepted as a useful tumor mar-ker for surveillance of gastrointestinal patients, especially with
colorectal neoplasm and several studies have used CEAmRNA
as a target marker to detect circulating tumor cells and high
expression levels have been correlated with poor survival.
Using nested RT-PCR for CEA, a large study was published
that reported detection of CEAmRNA in whole blood in
69% (n= 51) of colorectal carcinoma patients, whereas only
3% (n= 60) of apparently healthy donors were positive for
CEAmRNA [9].
Expression of CEAmRNA has been described recently in
76–80% of peripheral blood samples from patients with meta-
static carcinomas using nested PCR. This is in contrast to
other reports of detection of CEAmRNA in a signiﬁcant num-
ber of blood samples of healthy donors or in patients with
inﬂammatory bowel disease [28–31]. Abnormally high levels
of CEA protein in 30% of smokers should be taken into ac-
count [24].4.3. CK20
We found that CK20mRNA were signiﬁcantly more fre-
quently detected in the colon cancer patients than in healthy
controls and could serve as markers. CK20 appears to be a
sensitive marker for detection of disseminated tumor cells in
blood samples of intestinal cancer patients. Several studies
showed that CK20 is a reliable marker and not detectable in
the blood of non cancer patients. In contrast; RT-PCR ampli-
ﬁcation of CK20mRNA, which is considered as a promising
candidate in the method for the detection of circulating epithe-
lial cells, seems to lack speciﬁcity because its expression is not
limited to epithelial cells and an increasing number of false-
positives were observed in patients without cancer. Both an
illegitimate transcription and the presence of pseudogene have
been described to explain the possibility of false-positive re-
sults. The reported expression of CK20mRNA in the epider-
mal Merkel cells and granulocytes outlines the importance of
blood sampling technique and perfect elimination of contami-
nating granuloytes [27].
The relatively high positive ratio of CEA and
CK20mRNAs in the peripheral blood of CRC patients com-
pared with normal controls in our study indicates the exis-
tence of malignant tumor cells in their peripheral blood,
and further supports the hypothesis that CEA and
Detection of circulating tumor cells by nested RT-PCR targeting EGFR/CEA/CK20mRNAs 179CK20mRNAs are promising complementary markers for
CRC staging and prediction of cancer progression and metas-
tasis but false positive for CEA/CK20mRNAs seen in groups
of healthy donors limit its speciﬁcity. In particular CK20
which show lower speciﬁcity.
There is reported evidence to a signiﬁcant association of
disseminated cancer cell detection to an advanced stage
[28,29] which is in agreement with our result. On the other
hand, numerous studies reported that no correlation can be de-
tected between CEA and CK20mRNAs expression and the
clinicopathological characteristics of the disease [30].
The mRNA originated from circulating cancer cells is com-
monly detected in peripheral blood and RT-PCR shows higher
sensitivity than routine immunocytochemistry but the signiﬁ-
cance of such detection is still to be clariﬁed. The advantage
of the RNA identiﬁcation is that it implies that the cell is viable
since only viable cells produce mRNA and extracellular RNA
is rapidly degraded [1]. However, limitations may arise from
deﬁcient expression in circulating tumor cells or low level ille-
gitimate expression in hematopoietic cells, particularly if a
nested PCR approach is used.
Possible reasons contributing to a failure to detect circulat-
ing tumor cells include intertumoral variation in mRNA
expression of the tumor-associated protein used for RT-PCR
detection, resulting in varying detection thresholds between tu-
mors from different patients. In addition, experimental metas-
tasis studies suggest that circulating tumor cells are aggregated
in clumps of varying size, and this may result in a sample-to-
sample variation in the number of tumor cells contained within
different blood samples from the same patient. Thus, while pa-
tient positivity for circulating cancer cells is based on identiﬁ-
cation of one mRNA marker within a single blood sample, the
detection sensitivity might be limited by both the amount of
mRNA marker in circulating tumor cells and the number of
tumor cells in the blood sample [31]. Also, since cancer cells
are usually very heterogeneous, different cancers express dif-
ferent markers and even cells from the same tumor may not
be identical. Thus, single-marker RT-PCR has its limitations
in sensitivity and speciﬁcity. It has therefore been proposed
that the assessment of multiple tumor markers in one blood
sample would enhance the sensitivity of tumor cell detection.
But due to limited speciﬁcity as reported by Gradilone et al.
[32], further investigation is needed.
Recently Lagoudianakis et al. 2009; reported CEA/
CK20mRNAs were not detected in any sample of healthy con-
trols using OncoQuick Density Gradient Centrifugation. By
using tumor cell enrichment technique; speciﬁc cancer marker
detection could be improved [1,33,34].
The reason for discrepancy among various studies may be
multifactorial. The limited number of tested patients and in
the method of isolating circulating carcinoma cells may be con-
tributory factors; amount of cDNA; increasing amount of
DNA used increased sensitivity of the assay as reported by [2]
and the speciﬁcity of a RT-PCR assay is largely inﬂuenced by
several factors, among which the most important are: (a) carry-
over contamination, (b) illegitimate transcription, and (c) mar-
ker expression by non tumor cells in the sample. The best-
deﬁned problem in RT-PCR assays is carry-over contamina-
tion. The exponential ampliﬁcation method efﬁciently ampliﬁes
a few DNA copies one-million-fold to amounts of DNA that
are easily detectable on agarose gels. In addition to illegitimate
transcription, samples may be false-positive for a particularmarker because a small subset of the non tumor cells might ex-
press the transcript and the antigen; false positivity [35].
Although only 0.01% of circulating tumor cells survives the
passive transport in the blood stream and actually forms
metastasis at distant site, the quantiﬁcation of cancer cells re-
leased into the blood stream is a helpful piece of information
to allow precise diagnosis of the metastatic potential of the pri-
mary tumor in each individual case.
A standardization of blood sampling; multiple blood sam-
ple, RNA Preparation, cDNA preparation, gene-speciﬁc pri-
mer pairs, optimal RT-PCR conditions and the determination
of possible threshold caused by cells of non-tumor origin is
mandatory to obtain reliable and comparable results.
5. Conclusion
EGFR assay might represent a suitable marker for detection of
circulating tumor cells in colon cancer patients. That CEA and
CK20mRNAs are signiﬁcantly more frequently detected in co-
lon cancer patients than in healthy controls supports the
hypothesis that CEA and CK20mRNAs are promising comple-
mentary markers for CRC staging and prediction of cancer pro-
gression and metastasis. RT-PCR assays with multiple tumor
markers were shown to be superior in comparison to the assess-
ment of single markers but due to their limited speciﬁcity; fur-
ther data; investigation and clariﬁcation of the prognostic
signiﬁcance of genes and proteins implicated in metastatic pro-
cess in colon cancer needs to be further investigated.
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